Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

Table 3 The response of CRPC-associated AR mutations to anti-androgen treatments

AR mutants	Agonist response to treatment
AR mutants	Hydroxyflutamide	Bicalutamide	Enzalutamide	ARN509
L702H	Partial	Partial	No	No
V716M	Partial	Partial	No	No
V731M	Partial	Partial	No	No
W742L	Partial	Yes	No	No
W742C	Partial	Yes	No	No
H875Y	Yes	Partial	Partial	Partial
H875Q	Partial	Partial	No	No
F877L	Partial	No	Partial	partial
T878A	Partial	Yes	Partial	partial
T878S	Partial	Yes	Partial	partial
D880E	Partial	Partial	No	No
L882I	Partial	Partial	No	No
S889G	Yes	Yes	No	No
D891H	Yes	Yes	No	No
E894K	Partial	Partial	No	No
M896V	Partial	Yes	No	No
M896T	Partial	Yes	No	No
E898G	Partial	No	No	No
T919S	Partial	Partial	No	No
H875Q/T919S	Partial	Partial	No	No
T878A/S889G	Yes	Yes	Partial	Partial
T878A/D891H	Yes	Yes	Partial	No
F877L/ T878A	No	Yes	Yes	Yes
H875Y/T878A	Yes	Yes	Partial	Partial

Results presented in Additional file 4: Table S2 are summarized here. We considered as partial agonist a drug that inhibited a mutant at low concentrations and stimulated its activity at high concentrations

ISSN: 1474-760X